F408L

Category 3/4 — Most DruggableUncertain significanceTransmembrane · predictedSource card

Phenylalanine → Leucine at position 408 · Transmembrane helix 4 · WFS1 (Wolframin)

Interactive 3D Structure

Wild-type reference

Wild-type F408 — hydrogen bond to V412

Fullscreen ↗

DynaMut2 mutant · F408L

Mutant L408 — polar contact to S411 lost (4 contacts lost)

Fullscreen ↗

Bond changes · DynaMut2 interaction analysis

4 lost2 gained17 preserved

Interaction type	Wild-type partner	Mutant partner	Status
Hydrogen bond	P404	P404	Preserved
Hydrogen bond	Y405	Y405	Preserved
Hydrogen bond	S411	S411	Preserved
Hydrogen bond	V412	V412	Preserved
Polar contact	—	M357	Gained
Polar contact	P404	P404	Preserved
Polar contact	Y405	Y405	Preserved
Polar contact	A406	A406	Preserved
Polar contact	L410	L410	Preserved
Polar contact	S411	S411	Preserved
Polar contact	V412	V412	Preserved
Aromatic / π	W540	—	Lost
Van der Waals	—	M357	Gained
Van der Waals	A406	A406	Preserved
Van der Waals	L410	L410	Preserved
Van der Waals	V412	—	Lost
Hydrophobic	M357	M357	Preserved
Hydrophobic	C360	C360	Preserved
Hydrophobic	T361	T361	Preserved
Hydrophobic	V412	V412	Preserved
Hydrophobic	V536	V536	Preserved
Hydrophobic	M539	—	Lost
Hydrophobic	W540	—	Lost

Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.

Computational Predictions

DynaMut2 ΔΔG

-1.96kcal/mol

Destabilising — moderate

AlphaMissense

0.997

likely pathogenic

AlphaFold pLDDT

model confidence

Schema

Cat 3/4

Category 3/4 — Most Druggable

Clinical Evidence

ClinVar classificationUncertain significance

Review statuscriteria provided, single submitter

Associated conditionsInborn genetic diseases

Population frequency (gnomAD v4)Absent from gnomAD v4

cDNA changec.1224C>G

ClinVar accessionVCV004201394

Last evaluated2025/08/24 00:00

Not observed in ~730k individuals — consistent with a rare allele (ACMG PM2_supporting).

Full Variant Card

WFS1 Wolframin — F408L Variant Card

Molecular Atlas Pilot · RareResearch.AI · Generated by wolfram-variant-card skill

Phenylalanine → Leucine at position 408. Transmembrane helix 4. ClinVar Uncertain significance, AlphaMissense 0.997, DynaMut2 ΔΔG -1.96 kcal/mol (destabilising).

Identity

Field	Value
Variant	F408L (p.Phenylalanine408Leucine)
DNA change	c.1224C>G
Gene · Protein	WFS1 · Wolframin (890 aa)
UniProt	O76024 · WFS1_HUMAN
ClinVar accession	VCV004201394
Amino acid change	Phenylalanine (F) → Leucine (L)

Structural Context

Field	Value
AlphaFold model	AF-O76024-F1, v6
pLDDT at residue 408	93.00 — well-folded
Domain	Transmembrane helix 4
Position context	Inside Transmembrane helix 4 · position 408 is bilayer-embedded
IDR flag	No — pLDDT above 50 threshold

UniProt features at this position:

(none catalogued)

Position 408 sits in a transmembrane helix (Transmembrane helix 4). Wolframin has eleven such helices anchoring it in the ER membrane; substitutions inside the bilayer-embedded segments can disrupt helix packing, lipid contacts, and the overall ER topology of the protein. The wild-type residue is large aromatic hydrophobic (phenylalanine); the mutant is medium hydrophobic (leucine — branched). The chemistry shift implies altered local packing, hydrogen-bonding, and/or electrostatics at this site.

Computational Predictions

AlphaMissense

Field	Value
am_pathogenicity	0.9968
am_class	likely pathogenic
Interpretation	Likely pathogenic (threshold 0.564)

DynaMut2

Field	Value
ΔΔG (kcal/mol)	-1.96 (Destabilising)
Job ID	178092085778
Result URL	https://biosig.lab.uq.edu.au/dynamut2/results_prediction/178092085778

Clinical Evidence

Field	Value
Classification	Uncertain significance
Review status	criteria provided, single submitter
Last evaluated	2025/08/24 00:00
Inheritance	Inheritance pattern not specified in ClinVar entry; WFS1 has both AD and AR presentations.
WFS1 variant landscape	F408L is 1 of ~326 pathogenic-spectrum variants in WFS1 (out of 2,243 catalogued in ClinVar)

Inborn genetic diseases

Research Path Decision Tree

ΔΔG < 2  + binding site affected   →  CATEGORY 3 — docking experiments
ΔΔG 2–4                            →  CATEGORY 2 — pharmacological chaperones
ΔΔG > 4                            →  CATEGORY 1 — gene therapy
pLDDT < 50                         →  CATEGORY 5 — IDR, experimental only
Stable fold + functional site hit  →  CATEGORY 4 — site-specific docking

Final Schema Categorization

Category 3/4 — Most Druggable

<strong>Category 3/4 — Most Druggable</strong><br/><br/>|ΔΔG|=1.96 < 2 kcal/mol (fold intact) + AlphaMissense 0.997 confirms functional impact. Specific local contacts disrupted — priority for docking and pharmacological chaperone screening.

Why this card matters. Wolframin's fold survives this substitution (|ΔΔG|=1.96 kcal/mol). The pathogenic signal is real — AlphaMissense places it at 0.997. Protein still folds, but a specific local site is broken. Pharmacological chaperones and small-molecule binders are the rational therapeutic vector.

Files in this folder

AF-O76024-F1-model_v6.pdb — AlphaFold structure
F408L_molstar_viewer.html — interactive 3D viewer (auto-highlights position 408 with ball-and-stick + neighbors within 5Å)
F408L_variant_card.md — this card (source of truth)
F408L_variant_card.html — styled printable card
F408L_dynamut2_summary.html — clean offline DynaMut2 result card
dynamut2_result.json — structured result data
dynamut2_result_page.html — local snapshot of the Biosig result page (asset URLs absolutized)
F408L_wildtype_interactions.pse / F408L_mutant_interactions.pse — PyMOL sessions

Generated by wolfram-variant-card skill · RareResearch.AI Molecular Atlas Every assumption documented. Every score sourced.

Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the F408L PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download F408L PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.